cjc-1295 ipamorelin safety adverse effects clinical trials FDA Status: 2026 Compounding Guide CJC-1295 Peptide: Benefits, Science, &

June 2000

doi: 10.1007/s00223-021-00911-7 123 AtarashiKTanoueTShimaTImaokaAKuwaharaTMomoseYet al

Enemas are approved for this procedure by the FDA and worked in 25 out of 26 people in a clinical trial

The conversation includes informed consent that the evidence is preclinical-heavy and that the protocol is off-label

Treatment duration critically influences post-discontinuation outcomes with 6-12 month courses creating durable structural improvements supporting ongoing enhanced collagen synthesis without continuous peptide presence, while 2-3 month treatments produce temporary stimulation requiring continuous or cyclical application for maintaining optimal results

Quality Control and Product Sourcing Compounding pharmacies produce these peptides, so product quality matters enormously